Forte Biosciences Inc Stock Price, News & Analysis

Forte Biosciences (NASDAQ: FBRX) announced significant progress in its clinical development program for FB102, with three major trial readouts expected in 2026. The company has initiated a phase 2 trial in celiac disease following positive phase 1b results, continues enrollment in a phase 1b vitiligo study with data expected in 1H26, and is launching a phase 1b trial in alopecia areata.

On the financial front, Forte completed a successful public offering in June 2025, raising $69.9 million through the sale of 5.63M shares at $12.00 per share and pre-funded warrants, with an additional $1.7 million from the over-allotment exercise. The company ended Q2 2025 with $106.1 million in cash, reporting a net loss of $(0.96) per share compared to $(6.78) in Q2 2024.

Forte Biosciences (Nasdaq: FBRX), a clinical-stage biopharmaceutical company, has announced the pricing of a $75 million public offering. The offering consists of 5,630,450 shares of common stock priced at $12.00 per share, along with pre-funded warrants for up to 619,606 shares at $11.999 per warrant.

The company has granted underwriters a 30-day option to purchase up to an additional 937,508 shares. The offering is expected to close around June 26, 2025. Forte plans to use the proceeds for working capital, clinical and preclinical development of its product candidate, and other research activities.

Forte Biosciences (Nasdaq: FBRX), a clinical-stage biopharmaceutical company, has announced a proposed public offering of common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares.

The offering will be managed by TD Cowen, Evercore ISI, Guggenheim Securities, and Chardan as joint book-running managers, with Lucid Capital Markets as co-manager. Proceeds will be used for working capital, clinical and preclinical development of product candidates, and other research activities.

Forte Biosciences (NASDAQ: FBRX) reported positive Phase 1b trial results for FB102 in celiac disease treatment. The study enrolled 32 subjects (24 FB102, 8 placebo) who received 4 doses of FB102 (10 mg/kg) during a 16-day gluten challenge. FB102 showed statistically significant benefits in key metrics: composite histological VCIEL endpoint (p=0.0099), CD3-positive T cells density (p=0.0035), and a 73% improvement in Vh:Cd ratio compared to placebo. Patients treated with FB102 experienced 42% fewer GI symptoms during the gluten challenge. The treatment was well-tolerated with primarily mild adverse events and no grade 3 or higher SAEs. Following these positive results, Forte is initiating a Phase 2 trial with topline results expected in 2026. The company is also conducting FB102 trials for vitiligo, with results anticipated in H1 2026.

Forte Biosciences (NASDAQ: FBRX) reported its Q1 2025 financial results and provided clinical updates. The company is advancing its FB102 drug candidate with ongoing trials in celiac disease and vitiligo, with topline data from the celiac disease trial expected this quarter. FB102 has shown good tolerability with no dropouts. Financial highlights include: R&D expenses increased to $12.7M (vs $4.4M in Q1 2024), primarily due to manufacturing and clinical trial costs. The company reported a net loss of $1.37 per share, improved from $4.03 in Q1 2024. Forte ended Q1 2025 with $45.9M in cash and cash equivalents, with 6.6M shares of common stock and 4.8M prefunded warrants outstanding.

Forte Biosciences (NASDAQ: FBRX) reported its full year 2024 results and provided a clinical update. The company highlighted significant progress in developing FB102, with the completion of a healthy volunteer study and ongoing celiac patient trial, which is progressing well with no dropouts. Topline results are expected in Q2 2025.

Financial highlights include:

• R&D expenses decreased to $21.2M from $21.9M in 2023
• G&A expenses increased to $15.4M from $10.6M in 2023
• Net loss per share improved to $(12.17) from $(24.92)
• Year-end cash position of $58.4M

The company completed a 1:25 reverse stock split in August 2024 and raised $53.0M through an over-subscribed private placement in November 2024. As of December 31, 2024, there were 6.4M shares of common stock and 5.0M prefunded warrants outstanding.

Forte Biosciences (NASDAQ: FBRX), a clinical-stage biopharmaceutical company specializing in autoimmune and autoimmune-related diseases, has announced its participation in two major investor conferences. CEO Paul Wagner, PhD will deliver presentations at:

1. The Guggenheim SMID Cap Biotech Conference on February 6th at 1:30 PM ET in New York, NY at the Lotte New York Palace

2. The TD Cowen 45th Annual Healthcare Conference on March 3rd at 10:30 AM ET in Boston, MA at the Boston Marriott Copley Place

Forte Biosciences (NASDAQ: FBRX) has announced an upcoming R&D Day scheduled for December 3, 2024 at 4:30 p.m. ET. The event will spotlight the development of FB102 across autoimmune indications, featuring prominent experts in celiac disease, vitiligo, and alopecia areata.

Distinguished speakers include Prof. Jason Tye-Din from Walter and Eliza Hall Institute, Prof. Christopher Ma from University of Calgary, and Prof. David Rosmarin from Indiana University School of Medicine. These thought leaders will share insights on their respective fields of expertise in autoimmune-related diseases.

Forte Biosciences (NASDAQ: FBRX) has secured an oversubscribed $53 million private placement from leading healthcare institutional investors, including OrbiMed, Janus Henderson Investors, and Tybourne Capital Management. The funding will support the clinical advancement of FB102 across autoimmune indications. The company has completed its healthy volunteer study and is currently conducting a celiac disease trial with topline results expected in Q2 2025. Forte plans to expand FB102 development into additional indications over the next 12 months.